Vaxart Statistics
Total Valuation
Vaxart has a market cap or net worth of $140.13 million. The enterprise value is $118.75 million.
Important Dates
The next estimated earnings date is Thursday, August 7, 2025, after market close.
| Earnings Date | Aug 7, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Vaxart has 228.22 million shares outstanding. The number of shares has increased by 41.57% in one year.
| Current Share Class | 228.22M |
| Shares Outstanding | 228.22M |
| Shares Change (YoY) | +41.57% |
| Shares Change (QoQ) | +0.15% |
| Owned by Insiders (%) | 0.57% |
| Owned by Institutions (%) | 11.96% |
| Float | 226.93M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 2.81 |
| Forward PS | n/a |
| PB Ratio | 3.07 |
| P/TBV Ratio | 3.71 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 2.51 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.64, with a Debt / Equity ratio of 0.45.
| Current Ratio | 0.64 |
| Quick Ratio | 0.59 |
| Debt / Equity | 0.45 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -18.08 |
Financial Efficiency
Return on equity (ROE) is -114.74% and return on invested capital (ROIC) is -49.08%.
| Return on Equity (ROE) | -114.74% |
| Return on Assets (ROA) | -28.90% |
| Return on Invested Capital (ROIC) | -49.08% |
| Return on Capital Employed (ROCE) | -95.18% |
| Revenue Per Employee | $451,381 |
| Profits Per Employee | -$553,543 |
| Employee Count | 105 |
| Asset Turnover | 0.38 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, Vaxart has paid $310,000 in taxes.
| Income Tax | 310,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +16.91% in the last 52 weeks. The beta is 1.15, so Vaxart's price volatility has been higher than the market average.
| Beta (5Y) | 1.15 |
| 52-Week Price Change | +16.91% |
| 50-Day Moving Average | 0.43 |
| 200-Day Moving Average | 0.62 |
| Relative Strength Index (RSI) | 63.20 |
| Average Volume (20 Days) | 9,174,719 |
Short Selling Information
The latest short interest is 14.68 million, so 6.43% of the outstanding shares have been sold short.
| Short Interest | 14.68M |
| Short Previous Month | 14.35M |
| Short % of Shares Out | 6.43% |
| Short % of Float | 6.47% |
| Short Ratio (days to cover) | 8.30 |
Income Statement
In the last 12 months, Vaxart had revenue of $47.40 million and -$58.12 million in losses. Loss per share was -$0.27.
| Revenue | 47.40M |
| Gross Profit | -38.55M |
| Operating Income | -57.16M |
| Pretax Income | -75.38M |
| Net Income | -58.12M |
| EBITDA | -48.24M |
| EBIT | -57.16M |
| Loss Per Share | -$0.27 |
Full Income StatementBalance Sheet
The company has $41.94 million in cash and $20.56 million in debt, giving a net cash position of $21.38 million or $0.09 per share.
| Cash & Cash Equivalents | 41.94M |
| Total Debt | 20.56M |
| Net Cash | 21.38M |
| Net Cash Per Share | $0.09 |
| Equity (Book Value) | 45.62M |
| Book Value Per Share | 0.20 |
| Working Capital | -35.86M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$33.17 million and capital expenditures -$553,000, giving a free cash flow of -$33.73 million.
| Operating Cash Flow | -33.17M |
| Capital Expenditures | -553,000 |
| Free Cash Flow | -33.73M |
| FCF Per Share | -$0.15 |
Full Cash Flow StatementMargins
Gross margin is -81.34%, with operating and profit margins of -120.60% and -122.63%.
| Gross Margin | -81.34% |
| Operating Margin | -120.60% |
| Pretax Margin | -121.98% |
| Profit Margin | -122.63% |
| EBITDA Margin | -101.78% |
| EBIT Margin | -120.60% |
| FCF Margin | n/a |
Dividends & Yields
Vaxart does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -41.57% |
| Shareholder Yield | -41.57% |
| Earnings Yield | -41.48% |
| FCF Yield | -24.07% |
Dividend DetailsAnalyst Forecast
The average price target for Vaxart is $3.00, which is 388.60% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $3.00 |
| Price Target Difference | 388.60% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 2 |
| Revenue Growth Forecast (5Y) | 36.24% |
| EPS Growth Forecast (5Y) | 0.02% |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Vaxart has an Altman Z-Score of -4.67 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -4.67 |
| Piotroski F-Score | 4 |